Positron emission tomography with 2-[F-18]fluoro-2-deoxy-D-glucose in oncology Part II. The clinical value in detecting and staging primary tumours

Ak I., Stokkel M., Pauwels E.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.126, sa.10, ss.560-574, 2000 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 126 Sayı: 10
  • Basım Tarihi: 2000
  • Doi Numarası: 10.1007/pl00008466
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.560-574
  • Eskişehir Osmangazi Üniversitesi Adresli: Hayır

Özet

The tumoral uptake of 2-[F-18]fluoro-2-deoxy-D-glucose ((18)FdGlc) is based upon enhanced glycolysis. Positron-emission tomography (PET) using (18)FdGlc provides the physiological and metabolic information. (18)FdGlc PET has been used successfully for assessing primary rumours and metastases, prognosis, and planning and for monitoring tumour therapy as well as for early detection of recurrent tumour growth. This review summarises the uptake mechanism of (18)FdGlc in benign and malignant lesions, its relation to histolopathology, and its clinical value for detecting and staging primary tumours.